Treating obesity: is it all in the gut?

被引：11
作者：
Davenport, Richard J. [1 ]
Wright, Susanne [1 ]
机构：
[1] Takeda Cambridge, Dept Med Chem, Cambridge, England
来源：
DRUG DISCOVERY TODAY | 2014年 / 19卷 / 07期
关键词：
GLUCAGON-LIKE PEPTIDE-1; GASTRIC-INHIBITORY POLYPEPTIDE; FOOD-INTAKE; BARIATRIC SURGERY; WEIGHT-LOSS; PANCREATIC-POLYPEPTIDE; INSULIN-SECRETION; CONTROLLED TRIAL; MEDICAL THERAPY; BODY-WEIGHT;
D O I：
10.1016/j.drudis.2013.10.025
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Obesity is a leading cause of preventable mortality worldwide, with current strategies for treatment including life-style changes, pharmacological intervention and bariatric surgery. With pharmacological intervention showing at best modest patient benefits, new treatments are required. Modulation of anorectic gut hormones could offer the potential to elicit the required life-changing level of efficacy only currently seen with bariatric surgery, and without the cardiovascular risk associated with a number of the current marketed therapies. This review will discuss the gut hormones glucagon-like peptide-1 (GLP-1), Ghrelin and cholecystokinin (CCK) - for which more advanced non-peptide chemical matter has been discovered acting through these hormone pathways and/or their receptors.
引用
收藏
页码：845 / 858
页数：14
相关论文
共 95 条
[1]   The inhibitory effects of peripheral administration of peptide YY3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway [J].
Abbott, CR ;
Monteiro, M ;
Small, CJ ;
Sajedi, A ;
Smith, KL ;
Parkinson, JRC ;
Ghatei, MA ;
Bloom, SR .
BRAIN RESEARCH, 2005, 1044 (01) :127-131
[2]   DISTRIBUTION AND RELEASE OF HUMAN PANCREATIC POLYPEPTIDE [J].
ADRIAN, TE ;
BLOOM, SR ;
BRYANT, MG ;
POLAK, JM ;
HEITZ, P ;
BARNES, AJ .
GUT, 1976, 17 (12) :940-944
[3]   HUMAN DISTRIBUTION AND RELEASE OF A PUTATIVE NEW GUT HORMONE, PEPTIDE-YY [J].
ADRIAN, TE ;
FERRI, GL ;
BACARESEHAMILTON, AJ ;
FUESSL, HS ;
POLAK, JM ;
BLOOM, SR .
GASTROENTEROLOGY, 1985, 89 (05) :1070-1077
[4]  
Aicher B., 2011, Patent, Patent No. [WO2012035124, 2012035124]
[5]   Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery [J].
Alavijeh M.S. ;
Chishty M. ;
Qaiser M.Z. ;
Palmer A.M. .
NeuroRX, 2005, 2 (4) :554-571
[6]   Association of Pancreatitis with Glucagon-Like Peptide-I Agonist Use [J].
Anderson, Sarah L. ;
Trujillo, Jennifer M. .
ANNALS OF PHARMACOTHERAPY, 2010, 44 (05) :904-909
[7]  
[Anonymous], HLTH SURVEY ENGLAND
[8]  
Baroni M, 2010, World patent, Patent No. [WO2010092289, 2010092289]
[9]   BIOACTIVE ENTEROGLUCAGON (OXYNTOMODULIN) - PRESENT KNOWLEDGE ON ITS CHEMICAL-STRUCTURE AND ITS BIOLOGICAL-ACTIVITIES [J].
BATAILLE, D ;
GESPACH, C ;
TATEMOTO, K ;
MARIE, JC ;
COUDRAY, AM ;
ROSSELIN, G ;
MUTT, V .
PEPTIDES, 1981, 2 :41-44
[10]   Critical role for peptide YY in protein-mediated satiation and body-weight regulation [J].
Batterham, Rachel L. ;
Heffron, Helen ;
Kapoor, Saloni ;
Chivers, Joanna E. ;
Chandarana, Keval ;
Herzog, Herbert ;
Le Roux, Carel W. ;
Thomas, E. Louise ;
Bell, Jimmy D. ;
Withers, Dominic J. .
CELL METABOLISM, 2006, 4 (03) :223-233
12345678910